Heart rate lowering calcium antagonists (HRL-CA) in hypertensive post MI patients  by Messerli, Franz H. et al.
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grub, # of pls Total # of Pt months MI rate per 
with MI pts. Exposure T~me 1000 pt - yrs 
Ntfedfp~na GfTS 4 2.629 9,247 5.2 
Amlod~ne 22 25.853 68,675 3.9 
In a subset of comparative trials the incidence of MI among 1372 lots re- 
calving nifedipine GITS was 3.3/1000 pt-years while among 621 10ts receiving 
active agents other than CCB's it was 5.111000 pt-years (p = NS); and the 
incidence of MI among 3748 patients receiving amlodipine was 4.3/1000 
pt-ysars while among 927 patients receiving active agents other than CCB's 
it was 2.2/1000 pt-years (p = NS). These data st%'~ort the concept hat 
the lang.acting CCB's nifedipine GITS and amlodipine are safe for treating 
hypertension. 
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~7"~'-~--~ Heart Rate Calcium Antagonists (HRL-CA) Lowering 
in Hypertensive Post MI Pctlents 
Franz H. Messedi. William E. Baden, Jargen Fischer Hansan, Kenneth 
B. Schechtman. Ochsner Medical Institutions, New Orleans, LA; 
Washington University, $1. Louis, MO 
Two recent publications (JAMA 1995;274:620 and Circulation 1995;92:1328) 
have cast doubt on the safety of CAs. Previous mete-analysis (Am d Cardlol 
1991;67:1295) has shown that in the post MI patient not all CAs are cre- 
atsd equal and that some dihydropyddine CAs may be detrimental, whereas 
HRL-CAs (diltiazemNerapamil) may be beneficial. The present data are 
based on a post hoc analysis o1 pooled data obtained from 5,677 post MI 
patients, randomized to either a HRL-CA or placebo in the first and second 
Danish Verapamil Infarction Tdals (DAVIT I and II) and the Muificentsr Dil- 
tiazem Post Infarction Tdal (MDPIT). Mean follow-up was 550 4- 376 days, 
all-cause mortality was 16.3% in hypertensives (HTS) and 12.0% in nor- 
motensives (NTS), and event rates (death or MI) were 24.4% vs 17.8%. 
Mortality was slightly lower in patients on HRL-CAs than in those on placebo 
in both HTS (15.1% vs 17.5%) and NTS (11.7% vs 12.4%). However, cu- 
mulative event rates were significantly reduced by HRL-CAs in HTS as 
follows: 
Hypertensive Normotensive 
HRL-CA 142/667 21.4% 372/2159 17.2% 
Placebo 1801658 27.4% 402/2190 18.4% 
p = 0.004 0.319 
After adjusting for age, gander, a history of previous MI, and diabetes using 
Cox regression, the use of HRL-CAs in HTS was associated with significantly 
reduced event rates (p = 0.016), adjusted sk ratio 0.76 (95°/= confidence 
bounds ranging from 0.61-0.95). We conclude that treatment with HRL-CAs 
in HTS post MI patients significantly diminishes event rate whereas little 
effect is seen in NTS subjects. These data with HRL-CAs are in contrast 
with other r~.ports on dihydropyddine CAs showing no effect or an increase 
in events. 
3:00 
~ Effect of Gender on Relative Efficacy of Isradipine 
vs Hydrochlorothlazlde for Reduction of Left 
Ventdeuler Mass 
vasilios Papademetriou, John Gottdiener, Puneet Narayan. Veterans Affairs 
and Georgetewn University Medical Centers, Washington, D.C. 
In patients with hypertensive LVH, reduction of LV mass is a desirable goal of 
drug therapy. However, comparative data between men and women is scarce. 
In this 18 center single-blind, randomized trial we compared isradipine (ISR) 
and hydrochlorofhtazlde (HCTZ) In 134 pts (age 57 ± 10 years, BP 164 
21/110 ± 10 mm Hg, echo LVM 345 + 80 g ASE, 26 women). At 3 and 
6 months of therapy decreases in septal and posterior wall thickness were 
similar between ISR and HCTZ. However, decrease in LV mass was greater 
with HCTZ (-43 g) vs ISR (-11 gr, P < 0,01) due to decrease in diastolic LV 
size (-2.8 ram). Comparing the response of men and women the following 
results were obtained: 
LV Mass Change from Baseline 
Isredipine HGTZ 
Men (n=74) Women (n = 15) Men (n = 34) Women (n = 11) 
3Me -10.8' -17.3 -363** -7.6 
6 Me -7.3 -21.1 -48.1** -15.3 
2 Wk -8.2 0.8 -30.6 ,° -2.9 
Post 
*P < 0.03, **P = 0.001 ;P = Change from baseline 
It is concluded that LV mass reduction with HCTZ was limited to men. The 
response to ISR was small overall with a trend of greater LV mass reduction 
in women. Futlher studies are needed to confirm this observation, 
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~6- -~ Gender Differences in the Relationship Between 
Oisstollc Function and Oxygen Consumption in 
Hypertensive Subjects 
All G. Gheravi, Joseph A. DiamOnd, Neit L. Coplan, Adam Y. Goldman, 
Jeffrey S. Jhaog, Man~n Steinmelz, Robert A. Phillips. Mount Sinai School 
of Medicine & Lenox Hill Hospital, New York, NY 
Previous tudies have suggested that diastolic function is a major determinant 
of exercise capacity and oxygen consumption (VO2) in hypertension. To 
further evaluate the elfects of gender on determinants of VO2 (cc/kg/min), 
we studied 48 sedentary, asymptomatic, untreated hypertensive subjects (M 
= 31, F = 17; office BP = 1651107 + 19/12). All subjects underwent: 1) 24 hour 
ambulatory blood pressure monitoring, 2) resting 2-D directed M-mode and 
LV inflow Doppler echecardiography, 3) graded maximal bicycle ergometry 
with VO2 measurement. There wore no gender differences in age, BMI, 
office and 24 hr BP, resting heart rate, peak early (E), late (,6,) mitral inflow 
velocities and A/E ratio. Women had signflicantly lower LV mass, peak VO2 
and VO2 at anaerobic threshold. In men, peak VO2 was inversely related 
to peak A (r = -0.62, p < 0.0005), and age (r = -0.43, p < 0.02). On 
stepwise multiple regression analysis, only peak A remained signflicantly 
related to I~k  VO2 in men (r 2 = 0.39, P < 0.001). In women, there was no 
relationship ~oetwean any measure of diastolic function and VO2 at various 
levels o! exercise. On multiple regression analysis, only peak exercise BP 
was directly related to peak VO2 in women (r 2 = 0.33, P < 0.03). There 
are significant gender differenCes in determinants of VO2 in hypertensive 
subjects. Doppler determined iastolic function is a major predictor of VO2 
in men but not in women. 
[• Vein Graft  In tervent ions  
Tuesday, March 26, 1996, 4:00 p .m. -5 :30  p.m. 
Orange County Convention Center, Room 224 
4:00 
F7-6"1---1"-1 Randomized Trial of  Coronary Stent and Balloon 
Angloplasty in the Treatment of  Saphenous Veln 
Graft Stenosis 
John S. Douglas, Jr., Michael P. Savage, Steven R. Bailey, Cad J. Pepine, 
Jeffrey A. Wemer, Paul A. Overlie, Jeffrey A. Bdnker, David Fischman, 
Sheldon Goldberg, Spencer B. King III, SAVED Trial Investigators. Emory 
University School of Medicine, Atlanta, GA 
To compare the outcome of Palmaz-Schatz coronary stent (S) with balloon 
angioplasty (B), 215 patients with clinical evidence of ischemla and focal 
de novo vein graft stecoses were randomized at 12 centers. Demographic 
and clinical features of S and B groups were similar. Clinical events at 30 
days are reported in all patients and angiographic follow-up in ~ of eligible 
patients (last patient will be eligible for follow-up anglo in December 1995). 
Procedural success without cardiac complication was achieved in 90% of S 
and 78% of B patients (P < 0.015). 
Slant BallOOn P 
Clinical Events (%) at 30 days (IV = 215) 
Oeath 4 3 NS 
Non-QMTIQ wave MI 2/2 8/1 O.O59/NS 
CABG 2 4 NS 
Femoral repair 3 2 NS 
Transluelon I f 1 0.003 
Quantitative Anglogralohy (IV = 152 with 6 Month Follow-up) 
Baseline MUD (ram) 0.90 0.95 NS 
Postprocedura MLD (ram) 2.81 2.16 <0.0001 
MLD at 6 months tmm I 1.72 1.50 NS 
Immediate gain (mm) 1.90 1.19 <0.0001 
Lafe loss (ram) 1.I0 0.66 0.005 
Net gain (ram) 0.79 0.51 0.069 
Thus, stenting was associated with a higher procedural sucCess rate, 
a larger improvement in MLD, and a trend toward fewer non-Q MI, but 
significantly more transfusions. Interim analysis of late angiographic follow- 
up demonstrates ignificantly greater late lumen loss but a trend toward 
greater net gain after stenting. Complete six-month angiographic and clinical 
outcomes will be reported. 
